Drug Trial Radar · NCT00975143
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Last checked: Nov 20, 2026Latest source record: Jul 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
925
Actual
Start
Sep 2009
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Cipher Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 54 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.
Conditions
- Severe Nodular Acne
Interventions
CIP-IsotretinoinDrug
0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
IsotretinoinDrug
0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal)Time frame: 20 weeks
- Co-Primary Outcome 2: Proportion of Patients Who Achieve at Least a 90% Reduction in Total Number of Nodular Lesions (Facial and Truncal).Time frame: 20 weeks
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center
Birmingham, Alabama
Burke Pharmaceutical Research
Hot Springs, Arkansas
Center for Dermatology Clinical Research
Fremont, California
Dermatology Research Associates
Los Angeles, California
Dermatology Specialists
Oceanside, California
Skin Surgery Medical Group, Inc.
San Diego, California
Horizons Clinical Research Center
Denver, Colorado
North Florida Dermatology Associates, PA
Jacksonville, Florida
Ameriderm Research
Jacksonville, Florida
Park Avenue Dermatology
Orange Park, Florida
Ameriderm Research
Ormond Beach, Florida
Peachtree Dermatology Associates, PC
Atlanta, Georgia
MedaPhase Inc.
Newnan, Georgia
Northwest Clinical Trials
Boise, Idaho
Northwest Clinical Trials
Nampa, Idaho
Dawes Fretzin Clinical Research
Indianapolis, Indiana
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
The South Bend Clinic, LLP
South Bend, Indiana
Dermatology and Skin Cancer Specialists / Pediaresearch, LLC
Owensboro, Kentucky
ActivMed Practices & Research
Haverhill, Massachusetts
Great Lakes Research Group
Bay City, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
Skin Specialists, PC
Omaha, Nebraska
Comprehensive Clinical Research
Berlin, New Jersey
Haber Dermatology, Clinical Research Center
South Euclid, Ohio
Oregon Dermatology and Research Center
Portland, Oregon
Paddington Testing Company Inc.
Philadelphia, Pennsylvania
Radiant Research, Inc.
Greer, South Carolina
Dermatology Associates of Knoxville
Knoxville, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
Arlington Center for Dermatology
Arlington, Texas
Suzanne Bruce and Associates - The Center for Skin Research
Houston, Texas
Progressive Clinical Research
San Antonio, Texas
Stephen Miller, MD, PA Dermatology
San Antonio, Texas
Dermatology Research Center
Salt Lake City, Utah
Premier Clinical Research
Spokane, Washington
Derm Research @ 888 Inc.
Vancouver, British Columbia, Canada
Dermadvances Research
Winnipeg, Manitoba, Canada
Durondel C.P. Inc
Moncton, New Brunswick, Canada
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.